MedMesh.i
Checkpoint
PubMed
Racine
Checkpoint
PubMed
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Checkpoint (PubMed)

Index « MedMesh.i » - entrée « Health Care Costs »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Headache < Health Care Costs < Health Care Surveys  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 9.
Ident.Authors (with country if any)Title
000578 (2019) Ibrahim Khilfeh ; Eric Guyette [États-Unis] ; John Watkins [États-Unis] ; Dan Danielson [États-Unis] ; David Gross [États-Unis] ; Kai YeungAdherence, Persistence, and Expenditures for High-Cost Anti-Inflammatory Drugs in Rheumatoid Arthritis: An Exploratory Study.
000878 (2018) Tao Gu [États-Unis] ; Alex Mutebi ; Bradley S. Stolshek ; Hiangkiat TanCost of biologic treatment persistence or switching in rheumatoid arthritis.
000B33 (2017) Anagha Nadkarni [États-Unis] ; Donna Mcmorrow [États-Unis] ; Chad Patel [États-Unis] ; Robert Fowler [États-Unis] ; David Smith [États-Unis]Incidence of dose escalation and impact on biologic costs among patients with rheumatoid arthritis treated with three intravenous agents.
000E65 (2016) Alberto Batticciotto [Italie] ; Roberto Ravasio [Italie] ; Marta Riva [Italie] ; Piercarlo Sarzi-Puttini [Italie]Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate.
000F48 (2016) Benjamin Chastek [États-Unis] ; John White [États-Unis] ; Damon Van Voorhis [États-Unis] ; Derek Tang [États-Unis] ; Bradley S. Stolshek [États-Unis]A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
001155 (2015) Eiichi Tanaka [Japon] ; Eisuke Inoue ; Daisuke Hoshi ; Yoko Shimizu ; Akiko Kobayashi ; Naoki Sugimoto ; Kumi Shidara ; Eri Sato ; Yohei Seto ; Ayako Nakajima ; Shigeki Momohara ; Atsuo Taniguchi ; Hisashi YamanakaCost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study.
001226 (2014) R. Ariza [Oman] ; A. Van Walsem [Oman] ; C. Canal [Oman] ; C. Roldán [Oman] ; L. Beteg N [Oman] ; I. Oyagüez [Oman] ; K. Janssen [Oman][Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain].
001779 (2012) Alexander Diamantopoulos [Royaume-Uni] ; Maurizio Benucci ; Stefano Capri ; Wolfgang Berger ; Neil Wintfeld ; Giovanni Giuliani ; Walter RicciardiEconomic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy.
001807 (2012) Yee Chiu [Royaume-Uni] ; Andrew J K. Ostor ; Anthony Hammond ; Katharina Sokoll ; Marina Anderson ; Maya Buch ; Michael R. Ehrenstein ; Patrick Gordon ; Sophia Steer ; Ian N. BruceAccess to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: addressing treatment outside the current NICE guidance.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/MedMesh.i -k "Health Care Costs" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/MedMesh.i  \
                -Sk "Health Care Costs" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    indexItem
   |index=    MedMesh.i
   |clé=    Health Care Costs
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021